Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities.

efficacy hemodynamics tolerability

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
18 Feb 2022
Historique:
received: 11 12 2021
revised: 07 02 2022
accepted: 16 02 2022
entrez: 25 2 2022
pubmed: 26 2 2022
medline: 26 2 2022
Statut: epublish

Résumé

Riociguat is licensed for the therapy of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). We aimed to investigate whether age and comorbidities influence its tolerability and efficacy. Retrospectively, we analyzed data of tolerability, non-invasive, and invasive efficacy at baseline and follow up (FU) of all patients with CTEPH treated with riociguat at the Department of Internal Medicine V, University of Munich (

Identifiants

pubmed: 35207354
pii: jcm11041084
doi: 10.3390/jcm11041084
pmc: PMC8877433
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Ann Am Thorac Soc. 2016 Jul;13 Suppl 3:S248-54
pubmed: 27571006
Lancet Respir Med. 2021 Jun;9(6):573-584
pubmed: 33773120
J Heart Lung Transplant. 2017 May;36(5):509-519
pubmed: 28190787
Eur Heart J Suppl. 2019 Dec;21(Suppl K):K29-K36
pubmed: 31857798
Heart Fail Rev. 2019 Nov;24(6):949-965
pubmed: 31044326
N Engl J Med. 2013 Jul 25;369(4):330-40
pubmed: 23883378
Int J Cardiol. 2018 Dec 1;272S:37-45
pubmed: 30190158
Pulm Circ. 2015 Jun;5(2):296-304
pubmed: 26064454
Circulation. 2011 May 24;123(20):2263-73
pubmed: 21606405
Eur Heart J Suppl. 2019 Dec;21(Suppl K):K21-K28
pubmed: 31857797
Int J Cardiol. 2018 Dec 1;272S:69-78
pubmed: 30195840
Int J Cardiol Heart Vasc. 2019 Feb 28;22:163-168
pubmed: 30859124
N Engl J Med. 2013 Jul 25;369(4):319-29
pubmed: 23883377
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545968
Circulation. 2013 Jul 30;128(5):502-11
pubmed: 23775260
J Thorac Cardiovasc Surg. 2016 Sep;152(3):669-674.e3
pubmed: 27083940
Eur Respir J. 2017 Sep 9;50(3):
pubmed: 28889107
Eur Respir J. 2015 Oct;46(4):903-75
pubmed: 26318161
Eur Respir J. 2013 Apr;41(4):853-60
pubmed: 22936711

Auteurs

Michaela Barnikel (M)

Department of Internal Medicine V, Ludwig Maximilian University of Munich, 81377 Munich, Germany.
Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), 81377 Munich, Germany.

Nikolaus Kneidinger (N)

Department of Internal Medicine V, Ludwig Maximilian University of Munich, 81377 Munich, Germany.
Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), 81377 Munich, Germany.

Paola Arnold (P)

Department of Internal Medicine V, Ludwig Maximilian University of Munich, 81377 Munich, Germany.
Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), 81377 Munich, Germany.

Andrea Waelde (A)

Department of Internal Medicine V, Ludwig Maximilian University of Munich, 81377 Munich, Germany.

Jürgen Behr (J)

Department of Internal Medicine V, Ludwig Maximilian University of Munich, 81377 Munich, Germany.
Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), 81377 Munich, Germany.

Katrin Milger (K)

Department of Internal Medicine V, Ludwig Maximilian University of Munich, 81377 Munich, Germany.
Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), 81377 Munich, Germany.

Classifications MeSH